Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development
- Creative Medical Technology has achieved significant milestones in the development of its ImmCelz® platform. The platform requires 75% fewer donor cells, resulting in lower production costs. The final product has a purity of over 95% and a more potent effect on immune disorders. These advancements could positively impact the stock price.
- None.
Advancements May Result in Ability to Treat a Broader Patient Population with Immune Disorders
These advances support the Company's prior work in this area and confirm that the use of fewer donor cells can lower production costs while producing a more potent and efficacious final product.
In particular, independent studies confirmed:
- That the ImmCelz® (CELZ-100) platform required
75% fewer donor patient cells compared to industry standard; - That the purity of the final ImmCelz® (CELZ-100) product was greater than
95% compared to the industry standard of greater than80% ; - That ImmCelz® (CELZ-100) demonstrated a greater than
200% reduction in functional suppression of effector T cells, which are a critical concern for patients with autoimmune issues, while still possessing a high number of functional T regulatory cells; and - The ability to verify repeated potency of the final ImmCelz®(CELZ-100) product.
All experiments were independently conducted and validated on selected human donor patient cells for accuracy and reproducibility.
"We are thrilled to have achieved these important milestones in the development of our ImmCelz® (CELZ-100) platform, particularly the purity and functionality of the cells while substantially reducing the production costs," said Timothy Warbington, CEO of Creative Medical Technology Holdings. "We continue to be optimistic in the development of the ImmCelz® (CELZ-100) platform."
"We believe that our ability to reduce the number of donor patient cells by
About ImmCelz®
ImmCelz®, which is protected by trade secrets and published
The Company plans to advance multiple indications for ImmCelz® including Type I diabetes, heart disease, liver disease, and kidney disease.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, gynecology, and orthopedics and is traded on NASDAQ under the ticker symbol CELZ. For further information about the Company, please visit www.creativemedicaltechnology.com.
Forward Looking Statements
This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.
View original content to download multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-announces-next-milestone-achievements-in-immcelz-platform-development-301830389.html
SOURCE Creative Medical Technology Holdings, Inc.
FAQ
What is Creative Medical Technology Holdings focused on?
What are the advancements in the ImmCelz® platform?
How could these advancements affect production costs?
What is the potential impact of these advancements on patient treatment?